Rongtao Medical Receives Prestigious Bonded Repair Authorization for Ultrasound in China; NIPRO Introduces ELISIO™-HX Expanded Hemodialysis System to U.S. Market Following FDA Clearance; Lyric Health Unveils Asynchronous Care Solution for Smarter, Connected Virtual Care; New England Biolab® Strengthens Cell-Free RNA Workflow with Monarch® Mag Cell-free RNA Extraction Kit; Aqua Medical Advances Type 2 Diabetes Research with First U.S. Patient Treated at UNC Health; MediView XR90™ Holographic Surgical Navigation System Debuts in Florida at Cleveland Clinic Weston Hospital

Rongtao Medical Wins Bonded Repair Approval as One of the First in China for Ultrasound 

On 05 August 2026, Rongtao Medical received regulatory approval to conduct bonded repair services for imported ultrasound systems, becoming one of the earliest companies in China to obtain this qualification. The approval marked a significant advancement in the country’s medical device servicing capabilities by allowing ultrasound equipment to be repaired within bonded zones under an authorized framework. This development was expected to improve repair efficiency, shorten equipment downtime, and reduce maintenance expenses for healthcare institutions. The milestone also reinforced Rongtao Medical’s position in the ultrasound service industry while supporting the expansion of high-quality after-sales services for diagnostic imaging equipment across China.

“This approval closes the last gap between a strong technical repair offer and a genuinely frictionless international repair service,” said Frank Zhu, General Manager of Rongtao Medical. “For years, the hardest part of cross-border ultrasound repair for our customers has been logistics and customs, not electronics. A defined bonded channel replaces case-by-case workarounds with a clearly sanctioned path: no duties on their equipment, no temporary-import deposits, and end-to-end customs traceability.”

As per DelveInsight’s “Diagnostic Imaging Equipment Market Report,” the global diagnostic imaging equipment market is expected to increase from USD 51,560.07 million in 2025 to USD 82,258.46 million by 2034, reflecting strong and sustained growth. The Global Diagnostic Imaging Equipment Market is growing at a CAGR of 5.39% during the forecast period from 2026 to 2034. The Diagnostic Imaging Equipment Market is being primarily driven by the rising prevalence of chronic diseases such as cardiovascular disorders, cancer, neurological conditions, and orthopedic problems, which require early and accurate diagnosis. The growing aging population worldwide is another major factor, as elderly individuals are more prone to conditions that demand frequent imaging procedures like MRI, CT scans, ultrasound, and X-Rays.

NIPRO Launches Expanded Hemodialysis with ELISIO™-HX to U.S. Providers Following FDA Clearance 

On 04 August 2026, Nipro Corporation announced that it had received FDA 510(k) clearance for its ELISIO-HX hemodialyzer, supporting the introduction of the technology into the United States. The clearance represented an important regulatory milestone for the company as it expanded its hemodialysis portfolio in the U.S. market. The device was designed as a high-permeability hemodialyzer and was classified by the FDA as a Class II medical device under the high-permeability hemodialysis system category. The regulatory clearance enabled Nipro to strengthen its presence in the U.S. dialysis market and provided healthcare providers with an additional hemodialysis technology option. The development also reflected the continued advancement of dialyzer technologies aimed at supporting effective blood purification during dialysis treatment. Overall, the FDA clearance strengthened Nipro’s position in the U.S. hemodialysis devices market and contributed to the expansion of advanced dialyzer solutions available to dialysis providers.

“Innovation creates its greatest value when it becomes accessible in everyday clinical practice,” said Tsuyoshi Yamazaki, President & CEO of NIPRO CORPORATION. “Our ambition is to broaden the number of patients who can benefit from enhanced hemodialysis. With HDs, enabled by ELISIO-HX and our proprietary super high-flux membrane technology, healthcare professionals can enhance hemodialysis using the infrastructure and expertise they already have. FDA clearance represents an important milestone in bringing this approach to patients across the United States.”

As per DelveInsight’s “Hemodialysis Machines Market Report,” the global hemodialysis machines market was valued at USD 13.53 billion in 2023, growing at a CAGR of 4.71% during the forecast period from 2024 to 2030 to reach USD 17.78 billion by 2030. The increase in demand for Hemodialysis Machines is primarily attributed to the increasing prevalence of kidney disorders such as end-stage kidney disorder, kidney failure, and others. In addition, the constantly increasing old population, high blood pressure, and high diabetes prevalence are also driving factors for Hemodialysis Machines, as old age and diabetic people are more likely to develop kidney disorders. Moreover, technological advancement in the Hemodialysis Machines product pipeline and an increase in product approvals are among the other factors responsible for the growth of the global Hemodialysis Machines market during the forecast period from 2024 to 2030.

Lyric Health Introduced Asynchronous Care, Expanding Access to Smarter, More Connected Virtual Healthcare 

On 05 August 2026, Lyric Health expanded its virtual healthcare platform by introducing an asynchronous care capability that enabled patients to communicate with licensed healthcare professionals through secure digital messaging for clinically appropriate conditions. The new feature complemented the company’s existing video and telephone consultation services, offering an additional channel for accessing medical care.

The platform integrated patient-reported information with longitudinal clinical data, including electronic health records, laboratory results, pharmacy history, claims information, wearable device data, and previous virtual consultations. This comprehensive view supported clinicians in making more informed treatment decisions while improving care coordination.

The asynchronous care solution allowed healthcare providers to assess patient symptoms, review relevant medical information, recommend treatment, prescribe medications when appropriate, or escalate cases requiring real-time evaluation to live video or telephone consultations. The launch strengthened Lyric Health’s virtual care portfolio by improving healthcare accessibility, streamlining clinical workflows, increasing patient engagement, and supporting more efficient delivery of connected digital healthcare services.

“Healthcare isn’t just facing an access problem; it’s facing an information problem,” said Rey Colón, Chief Executive Officer of Lyric Health. “Patients often wait weeks for an appointment, and when they finally see a provider, that clinician may not have the complete picture. Lyric changes that by combining intelligent technology with connected health information to create a faster, more personalized care experience.”

As per DelveInsight’s “Telehealth Market Report,” the global telehealth market is expected to increase from USD 209,983.60 million in 2025 to USD 2,458,662.53 million by 2034, reflecting strong and sustained growth. The Global Telehealth Market is growing at a CAGR of 31.81% during the forecast period from 2026 to 2034. The Telehealth Market is being primarily driven by the rising prevalence of chronic disorders, which is driving the need for regular consultations and continuous monitoring, which Telehealth efficiently provides. At the same time, the widespread adoption of smartphones, high-speed internet, and wearable health devices enables seamless remote consultations and real-time health tracking. Additionally, increased product development activities by key market Telehealth Companies are introducing innovative Telehealth solutions, improving service quality, and expanding accessibility. Together, these drivers are accelerating Telehealth adoption, enhancing patient engagement, and expanding the overall market.

New England Biolab® Launched Monarch® Mag Cell-free RNA (cfRNA) Extraction Kit to Enable Total cfRNA Isolation from Biofluids 

On 04 August 2026, New England Biolabs introduced the Monarch® Mag Cell-free RNA (cfRNA) Extraction Kit to support the isolation of total circulating cell-free RNA from a wide range of biofluids, including plasma, serum, urine, and cerebrospinal fluid. The product expanded the company’s portfolio of nucleic acid extraction solutions and strengthened end-to-end workflows for cell-free nucleic acid analysis.

The magnetic bead-based, phenol-free workflow was designed to improve the recovery of low-abundance circulating RNA while incorporating DNase treatment to minimize DNA contamination and enhance the quality of downstream sequencing and amplification applications. The extraction technology also addressed the preservation of small RNA molecules, supporting more reliable transcriptomic analyses.

The kit was developed with flexibility for different sample volumes, compatibility with laboratory automation platforms, and ambient-temperature shipping through stabilized reagents. The product launch reinforced New England Biolabs’ position in the molecular biology and genomics research markets by advancing sample preparation technologies for liquid biopsy, biomarker discovery, precision medicine, and next-generation sequencing applications.

“While cfDNA has been the standard nucleic acid analyte in liquid biopsies, cfRNA carries information cfDNA cannot: which tissue a signal came from, and how pathology is changing over time,” stated Anagha Kadam, Applications and Product Development Scientist II at NEB. “This kit offers researchers consistent recovery of low-abundance cfRNA and removal of DNA contamination so they can assess this valuable but under-investigated analyte.”

According to DelveInsight’s “Liquid Biopsy in Cancer Diagnostics Market Report”, the global liquid biopsy in cancer diagnostics market was valued at USD 7.64 billion in 2025 and is expected to reach USD 19.24 billion by 2034. The global liquid biopsy in cancer diagnostics market is expected to grow at a CAGR of 16.64% during the forecast period from 2026 to 2034. Factors such as the rising incidence of various cancers, growing demand for minimally invasive procedures, increasing demand for precision medicine, and technical innovation in product development, among other factors, are expected to drive the liquid biopsy in cancer diagnostics market.

Aqua Medical Treats First U.S. Patient for Type 2 Diabetes at UNC Health Using Investigational Through-The-Scope Endoscopic Therapy

On 28 July 2026, Aqua Medical achieved an important clinical milestone by treating the first U.S. patient in its FDA-authorized Investigational Device Exemption (IDE) trial evaluating its Proximal Intestinal Mucosal Ablation (PIMA) procedure for type 2 diabetes. The procedure was performed at UNC Health in North Carolina and represented the beginning of the company’s U.S. clinical evaluation of its investigational endoscopic metabolic therapy. PIMA used a proprietary radiofrequency vapor ablation platform delivered through the working channel of a standard endoscope to treat a targeted portion of the proximal small intestine. The approach was designed to address abnormal metabolic signaling associated with insulin resistance and promote the restoration of healthier intestinal metabolic signaling. Before initiating the U.S. trial, Aqua Medical had treated 66 patients through its international clinical program, generating safety and clinical data that supported the U.S. study. Unlike conventional interventional approaches, the procedure was performed through a standard endoscope without fluoroscopy and was designed as a minimally invasive outpatient treatment. The clinical trial evaluated the safety and effectiveness of PIMA in adults whose type 2 diabetes remained inadequately controlled despite standard medical therapy. The advancement strengthened the development of minimally invasive, procedure-based treatment options for type 2 diabetes and supported growth opportunities in the endoscopic metabolic therapy and diabetes treatment devices markets.

According to DelveInsight’s ”Minimally Invasive Surgical Devices Market Report,” The global minimally invasive surgical devices market is expected to increase from USD 30,798.01 million in 2025 to USD 53,259.85 million by 2034, reflecting strong and sustained growth. The global minimally invasive surgical devices market is growing at a CAGR of 7.13% during the forecast period from 2026 to 2034. The demand for minimally invasive surgical devices is being primarily driven by the rising prevalence of chronic diseases such as cancer and cardiovascular disorders, among others. Additionally, the global increase in the number of surgical procedures being performed using minimally invasive techniques, coupled with growing technological advancements and an increase in product development activities among the key market players, are key factors contributing to the positive growth of the minimally invasive surgical devices market during the forecast period from 2026 to 2034.

MediView XR, Inc. and Cleveland Clinic Weston Hospital Complete First-Ever Intraprocedural Use of the MediView XR90™ Holographic Surgical Navigation System in Florida 

On 04 August 2026, MediView XR, Inc. and Cleveland Clinic Weston Hospital completed the first intraprocedural use of the XR90 holographic surgical navigation system in Florida. The milestone marked the first clinical deployment of the extended reality (XR) surgical navigation platform at the hospital and represented an important advancement in image-guided interventional procedures within the state.

The system was utilized during a percutaneous liver biopsy, where it combined preoperative CT images with real-time ultrasound to generate a three-dimensional holographic view of the patient’s anatomy. This integrated visualization enabled clinicians to accurately identify and access a deeply located liver lesion while supporting precise needle guidance during the procedure.

The technology was designed to improve procedural accuracy, reduce reliance on ionizing radiation during interventions, and provide an ergonomic workflow by allowing physicians to visualize patient anatomy directly within their field of view instead of shifting attention between multiple imaging displays. The successful procedure strengthened the clinical adoption of holographic surgical navigation and reinforced the growing role of augmented reality technologies in minimally invasive and image-guided interventions.

“This new imaging modality and intuitive visualization can be a game changer because we’re creating a holographic three-dimensional image that’s actually overlaid into the patient,” said Dr. Stadtlander. “As we perform this procedure, we’re seeing into the patient’s body three-dimensionally without any X-rays. In essence, we have ‘X-ray vision,’ but there’s no radiation involved.

According to DelveInsight’s “Surgical Navigation Systems Market Report,” The global surgical navigation systems market was valued at USD 7,753.34 million in 2023, growing at a CAGR of 6.76% during the forecast period from 2024 to 2030. The demand for surgical navigation systems is primarily being boosted by the increasing prevalence of various chronic diseases such as stroke, Alzheimer’s, cerebrovascular disease, and others. Further, the rising incidence of orthopedic disorders, especially among the geriatric population, along with increasing demand for minimally invasive surgical procedures and growing activities for research and development for surgical navigation systems, are thereby contributing to the overall growth of the surgical navigation systems market during the forecast period from 2024-2030.